Patents Assigned to Cubist Pharmaceuticals, Inc.
  • Patent number: 5726195
    Abstract: Certain novel aminoacyl adenylate mimics are described. An exemplary compound of this invention is ?S-(R*,R*)!-3,6-anhydro-1,2-dideoxy-1-?5-?4-?(5-nitro-2-thienyl)ethynyl!ph enyl!-2H-tetrazol-2-yl!-D-allo-heptitol 7-(2-amino-3-methyl-1-oxopentyl)sulfamate. These compounds inhibit isoleucyl-tRNA synthetases and are useful as antimicrobial and antiparasitic agents.
    Type: Grant
    Filed: July 16, 1996
    Date of Patent: March 10, 1998
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Jason M. Hill, Guixue Yu, Youe-Kong Shue, Thomas M. Zydowsky, Julius Rebek
  • Patent number: 5656470
    Abstract: Isolated and/or recombinant nucleic acids encoding mycobacterial seryl-tRNA synthetase have been characterized. Recombinant DNA constructs and vectors having a sequence which encodes mycobacterial seryl-tRNA synthetase have been made, and can be used for the construction of tester strains as well as for the production of isolated and/or recombinant seryl-tRNA synthetases. These enzymes or portions thereof are useful in the biochemical separation of serine and quantification of serine or ATP, and for producing antibodies useful in the purification and study of the enzyme, for example. Host cells and methods useful for producing recombinant mycobacterial seryl-tRNA synthetases are described, as are tester strains, which are cells engineered to rely on the function of the tRNA synthetase encoded by an introduced cloned gene.
    Type: Grant
    Filed: September 13, 1994
    Date of Patent: August 12, 1997
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Susan A. Martinis, Jiansu Zhang, Paul R. Schimmel
  • Patent number: 5629188
    Abstract: Isolated, recombinant nucleic acids which encode alanyl-tRNA synthetase (AlaRS) of human origin have been used to make expression constructs and transformed host cells for the production of recombinant human AlaRS. The recombinant enzyme has been purified, and is active in the specific aminoacylation of tRNA by alanine. The isolated, recombinant human AlaRS is also recognized by antibodies made by patients with the particular autoimmune disease known as "antisynthetase syndrome" in which the patients produce antibodies against the human alanyl-tRNA synthetase in their own cells. Thus, the isolated, recombinant enzyme, and antibodies made specifically thereto, can be useful in assays to diagnose and monitor this disease. The essential alanyl-tRNA synthetases of microbes pathogenic in humans can be the targets of inhibitory agents having antimicrobial activity.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: May 13, 1997
    Assignees: Cubist Pharmaceuticals, Inc., Cancer Institute, Japanese Foundation for Cancer Research, Massachusetts Institute of Technology
    Inventors: Kiyotaka Shiba, Paul R. Schimmel, Tracy L. Ripmaster